IsoRay touts another ‘100%’ study

June 20, 2017 By Fink Densford Leave a Comment

IsoRay (NYSE:ISR) today released data from a study of its Cesium-131 brachytherapy for treating patients with large brain metastases, touting a 100% freedom from local progression.

Results from the study were published in the International Journal of Radiation Oncology, Biology, Physics, the Richland, Wash.-based company said.

In the study, researchers assessed the impact of low-dose rate Cesium-131 brachytherapy on local control and radionecrosis in 42 patients treated for a total of 46 large brain metastases. Patients in the trial underwent surgical resection with intra-operative palcement of standard Cesium-131 seeds as permanent volume implants in the resection cavity, the company said.

Results from the trial indicated a 100% freedom from local progression rate, meaning brain metastases did not re-grow, and a 0% rate of radionecrosis. Study authors concluded that the Cesium-131 brachytherapy was “safe and effective adjuvant therapy for large brain metastases requiring neurosurgical intervention,” the company said.

“Evidence of Cesium-131’s efficacy in treating brain cancer continues to increase as supported by this important study. The work of Drs. Wernicke and Schwartz is truly pioneering and provides hope that we can continue to improve the available treatment for those afflicted with brain metastases. Treatment of brain metastases is a large unmet need and we’re gratified that our Cesium-131 product has promise to be effective for the many in need,” chief scientific officer Bill Cavanagh said in a press release.

Previous claims of 100% results from IsoRay have been met with serious criticism. In March, Isoray won approval for a $3.5 million settlement related to a class action suit brought against it last June in which shareholders claimed the company had made misleading statements about the 1st trial of its Cesium-131.

In the suit, investors accused the company of making false or misleading statements about the 1st major peer-reviewed study of its brachytherapy seeds in its own press release.

The company’s press release came out May 20, 2016, 1 day after the study was published in the journal Brachytherapy. IsoRay’s release claimed a 100% survival rate at 5 years in high-risk patients and a 96% success rate in local tumor control. ISR shares surged on the news, more than doubling to $3.12 apiece by the market’s close May 20.

But the next day TheStreet.com published an article criticizing IsoRay’s claims, challenging the company’s interpretation of the data and accusing IsoRay of publishing false claims to inflate its stock value. The Brachytherapy report found that other treatments showed statistically equivalent survival and local tumor control rates. IsoRay shares fell 35.3% to a $2.02-per-share close May 21

The company initially announced the settlement last Sept., but stipulated that the settlement was “subject to a number of conditions” including final court approval, and said that it would communicate to potential class members before a decision is made.

Could this 3D bioink printer speed wound healing?
The University of Toronto is touting a new handheld 3D printer that can deposit sheets of skin to cover burn wounds and accelerate the healing process. A study, led by Richard Cheng under the supervision of Axel Guenther, published in Biofabrication revealed that the 3D printer completed successful in-vivo trials on full-thickness wounds, according to a report… […]
8 types of FDA-approved devices that treat the heart
Just starting to learn about all of the medical devices out there for treating cardiovascular diseases? The U.S. FDA has a good, basic roundup on its website of the most common types of cardiovascular devices it regulates. Here’s the list, along with the FDA’s descriptions: 1. Automated external defibrillators (AEDs) “Portable and automatic, these devices… […]
Medtronic seeks to boost surgical robotics play with Digital Surgery acquisition
Medtronic (NYSE:MDT) announced today that it has acquired Digital Surgery (London), a privately-held pioneer in surgical artificial intelligence, data and analytics, and digital education and training. Financial terms of the deal were not disclosed. Medtronic said the purchase will strengthen its robot-assisted surgical platform and its broader portfolio. The medical device giant is making a big play… […]
Solvay expands advanced materials offerings in the medtech space
Solvay, a supplier of advanced materials and specialty chemicals, announced a pair of advances that it hopes will help it expand its healthcare business. Speaking yesterday at Solvay’s booth (#2414) at MD&M West, the company’s healthcare sales development manager Rose Catherin said the new materials will help improve the performance of specialty surgical devices including… […]
11 states ask EPA to crack down on ethylene oxide emissions
Eleven state attorneys general are urging the U.S. Environmental Protection Agency to impose stricter regulations over commercial operations that emit ethylene oxide (EtO), a widely used medical device sterilant gas. The EPA, which considers EtO a carcinogen, has been fielding comments on it in light of public outcry over emissions from medtech sterilization plants during… […]
Is it possible to ‘knit’ replacement blood vessels?
A new way to replace a patient’s damaged blood vessels may be on its way, as researchers in France are figuring out a way to “knit” new vessels with a collagen-based extracellular matrix. Inserm researcher Nicolas L’Heureux and his colleagues at Inserm/Université de Bordeaux’s tissue bioengineering unit published a study in Acta Biomaterialia to outline… […]
Applied Plastics has a new website, online store
Applied Plastics (Norwood, Mass.) — maker of PTFE-coated products for advanced catheter systems — announced today that it is rebranding to improve its customer interface and support continued growth. The rebranding includes a new website, online store and refreshed brand identity. The company this week is showing off the new look and its online PTFE… […]
How to select miniature motors for surgical robotics
Surgical robotics is leveraging the same sterilizable brushless direct current (BLDC) motors already used for decades in surgical hand tools. It’s all about torque, speed and reliability — as well as sterilization requirements. Keith Halbert, Portescap Today’s surgical robotics and robotically-assisted surgical devices often require BLDC motors to meet demanding requirements. While motors and motion… […]
What is an autoclave cycle?
Keith Halbert, Portescap The most common sterilization method used in hospitals is autoclaving, also called steam sterilization. During autoclaving, surgical handtools are exposed to 100% humidity, 135ºC (275ºF) and pressure variations for up to 18 minutes. Most autoclaves also have additional vacuum cycles to facilitate steam penetration and kill viruses, fungi, bacteria, and spores that… […]
BioIntelliSense wins FDA nod for BioSticker continuous vital sign monitor
BioIntelliSense announced that it won FDA 510(k) clearance for its BioSticker on-body sensor for scalable remote care and initiated the U.S. commercial launch of the product last week. The BioSticker is designed to allow for continuous monitoring of vital signs and actionable insights to provide opportunities for early detection of potentially avoidable complications from a home… […]
Accu-Tube acquires Mercury Tube
Stainless steel tubing outfit Accu-Tube announced today that it has acquired Mercury Tube, another metal tube manufacturer in its home base of Englewood, Colo. Mercury Tube, which makes high-precision stainless steel and high nickel alloy tubing, will operate as a wholly-owned subsidiary of Accu-Tube. Financial terms of the deal were not disclosed. Get the full… […]